Chan Dick C, Watts Gerald F, Redgrave Trevor G, Mori Trevor A, Barrett P Hugh R
Department of Medicine, University of Western Australia and the Western Australian Institute for Medical Research, Royal Perth Hospital, Perth, Australia.
Metabolism. 2002 Aug;51(8):1041-6. doi: 10.1053/meta.2002.33339.
Obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. We aimed to test the hypothesis that kinetics of hepatic apolipoprotein B-100 (apoB) metabolism are disturbed in men with visceral obesity and to examine whether these kinetic defects are associated with elevated plasma concentration of apolipoprotein C-III (apoC-III). Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) apoB kinetics were measured in 48 viscerally obese men and 10 age-matched normolipidemic lean men using an intravenous bolus injection of d(3)-leucine. ApoB isotopic enrichment was measured using gas chromatography-mass spectrometry (GCMS). Kinetic parameters were derived using a multicompartmental model (Simulation, Analysis, and Modeling Software II [SAAM-II]). Compared with controls, obese subjects had significantly elevated plasma concentrations of plasma triglycerides, cholesterol, LDL-cholesterol, VLDL-apoB, IDL-apoB, LDL-apoB, apoC-III, insulin, and lathosterol (P <.01). VLDL-apoB secretion rate was significantly higher (P =.034) in obese than control subjects; the fractional catabolic rates (FCRs) of IDL-apoB and LDL-apoB (P <.01) and percent conversion of VLDL-apoB to LDL-apoB (P <.02) were also significantly lower in obese subjects. However, the decreased VLDL-apoB FCR was not significantly different from the lean group. In the obese group, plasma concentration of apoC-III was significantly and positively associated with VLDL-apoB secretion rate and inversely with VLDL-apoB FCR and percent conversion of VLDL to LDL. In multiple regression analysis, plasma apoC-III concentration was independently and significantly correlated with the secretion rate of VLDL-apoB (regression coefficient [SE] 0.511 [0.03], P =.001) and with the percent conversion of VLDL-apoB to LDL-apoB (-0.408 [0.01], P =.004). Our findings suggest that plasma lipid and lipoprotein abnormalities in visceral obesity may be due to a combination of overproduction of VLDL-apoB particles and decreased catabolism of apoB containing particles. Elevated plasma apoC-III concentration is also a feature of dyslipidemia in obesity that contributes to the kinetic defects in apoB metabolism.
肥胖与血脂异常密切相关,这可能是动脉粥样硬化和冠心病相关风险增加的原因。我们旨在验证以下假设:内脏肥胖男性肝脏载脂蛋白B-100(apoB)代谢动力学存在紊乱,并研究这些动力学缺陷是否与载脂蛋白C-III(apoC-III)血浆浓度升高有关。使用静脉推注d(3)-亮氨酸的方法,对48名内脏肥胖男性和10名年龄匹配的血脂正常的瘦男性进行极低密度脂蛋白(VLDL)、中间密度脂蛋白(IDL)和低密度脂蛋白(LDL)apoB动力学测量。使用气相色谱-质谱联用仪(GCMS)测量apoB同位素富集情况。使用多室模型(模拟、分析和建模软件II [SAAM-II])得出动力学参数。与对照组相比,肥胖受试者的血浆甘油三酯、胆固醇、低密度脂蛋白胆固醇、VLDL-apoB、IDL-apoB、LDL-apoB、apoC-III、胰岛素和羊毛甾醇的血浆浓度显著升高(P <.01)。肥胖受试者的VLDL-apoB分泌率显著高于对照组(P =.034);肥胖受试者IDL-apoB和LDL-apoB的分解代谢分数率(FCRs)(P <.01)以及VLDL-apoB向LDL-apoB的转化率百分比(P <.02)也显著降低。然而,VLDL-apoB FCR的降低与瘦组无显著差异。在肥胖组中,apoC-III的血浆浓度与VLDL-apoB分泌率显著正相关,与VLDL-apoB FCR以及VLDL向LDL的转化率呈负相关。在多元回归分析中,血浆apoC-III浓度与VLDL-apoB的分泌率(回归系数[标准误] 0.511 [0.03],P =.001)以及VLDL-apoB向LDL-apoB的转化率(-0.408 [0.01],P =.004)独立且显著相关。我们的研究结果表明,内脏肥胖中的血浆脂质和脂蛋白异常可能是由于VLDL-apoB颗粒过度产生和含apoB颗粒分解代谢减少共同导致的。血浆apoC-III浓度升高也是肥胖血脂异常的一个特征,它导致了apoB代谢的动力学缺陷。